Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash from Financing Activities (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Cash from Financing Activities data on record, last reported at $72.6 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 68.96% year-over-year to $72.6 million; the TTM value through Sep 2025 reached $76.3 million, down 81.44%, while the annual FY2024 figure was $413.0 million, 1952.88% up from the prior year.
  • Cash from Financing Activities reached $72.6 million in Q3 2025 per ZBIO's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $234.0 million in Q3 2024 and bottomed at -$614000.0 in Q1 2024.
  • Average Cash from Financing Activities over 3 years is $60.9 million, with a median of $1.8 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 3606.0% in 2024, then crashed 99.03% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $50000.0 in 2023, then surged by 3606.0% to $1.9 million in 2024, then skyrocketed by 3818.83% to $72.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $72.6 million in Q3 2025, $1.7 million in Q2 2025, and $99000.0 in Q1 2025.